Zacks Investment Research Lowers Corium International Inc (CORI) to Sell
Corium International Inc (NASDAQ:CORI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
A number of other research analysts have also recently issued reports on CORI. FBR & Co reissued a “buy” rating on shares of Corium International in a research report on Thursday, June 16th. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Corium International in a research report on Thursday, June 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Corium International has an average rating of “Buy” and an average price target of $11.92.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/zacks-investment-research-lowers-corium-international-inc-cori-to-sell.html
Shares of Corium International (NASDAQ:CORI) traded down 5.79% during mid-day trading on Tuesday, reaching $5.53. 13,028 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $5.79 and a 200-day moving average price of $4.59. The stock’s market cap is $123.65 million. Corium International has a one year low of $3.14 and a one year high of $9.93.
Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. Corium International had a negative net margin of 104.77% and a negative return on equity of 158.38%. On average, analysts predict that Corium International will post ($1.62) EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of CORI. Franklin Resources Inc. boosted its position in shares of Corium International by 1.4% in the first quarter. Franklin Resources Inc. now owns 818,290 shares of the biopharmaceutical company’s stock valued at $3,158,000 after buying an additional 11,200 shares during the period. State Street Corp boosted its position in shares of Corium International by 82.4% in the first quarter. State Street Corp now owns 132,615 shares of the biopharmaceutical company’s stock valued at $511,000 after buying an additional 59,905 shares during the period. Geode Capital Management LLC boosted its position in shares of Corium International by 1.6% in the first quarter. Geode Capital Management LLC now owns 76,871 shares of the biopharmaceutical company’s stock valued at $296,000 after buying an additional 1,187 shares during the period. Opaleye Management Inc. boosted its position in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares during the period. Finally, RTW Investments LLC boosted its position in shares of Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock valued at $2,960,000 after buying an additional 24,629 shares during the period. 88.15% of the stock is owned by institutional investors and hedge funds.
Corium International Company Profile
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc and related companies with MarketBeat.com's FREE daily email newsletter.